download now

Houston tech company launches app to upgrade mobile ordering

A Houston startup is making mobile food ordering a whole lot easier within health care facilities. Photo by Jonas Leupe on Unsplash

A Houston tech company has launched its mobile ordering app, the company announced last week.

Rivalry Tech, which created sEATz, an in-seat food delivery platform for sports and entertainment venues, has launched myEATZ in the App Store and Google Play. The platform is designed for facilities with 24/7/365 dining needs, and the app's initial focus is on the health care industry.

Health care employees work long shifts and have to optimize their break time. With the myEATZ app, these workers can order ahead and skip the line at nearby eateries. For Rivalry Tech's co-founder and CEO, Aaron Knape, being able to provide this tool to health care workers is a personal win for him.

“Being married to a nurse, and living next door to the largest medical center in the world, I’ve seen the challenges faced by healthcare workers the past few years," he says in a news release. "To offset long hours and short breaks, the myEATz platform can truly give time back to healthcare workers by letting them skip the line.”

Outside of health care, myEATz has also identified opportunities within the hospitality industry. Last year, myEATz launched at Margaritaville Lake Conroe to allow guests to mobile order food and beverage directly to their pool chair. The expansion is in its second phase with plans to rollout into other hotels.

Originally founded as sEATz in 2018 by Knape, Marshall Law, and Craig Ceccanti, Rivalry Tech raised $3.5 million in November. The round was led by Houston-based Sightcast, with participation from Houston-based Softeq Venture Studio, Rice University’s Valhalla Investment Group, and more.

The myEATz app is available now. Image courtesy of Rivalry Tech

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted